Patent Reform: The Plight of Today’s Innovator
Are today’s US Patents a bait and switch for innovators of tomorrow’s crucial technologies? Are we sacrificing the future investment in U.S. innovation in a mania to stop abusive patent…
Not the Breast Outcome for Myriad Genetics
The United States and Australia share some pretty significant legal differences. For example, rigid gun control laws in Australia compared to the constitutional right to bear arms in the United…
Let’s Be Reasonable! In re Cuozzo & PTAB’s Broadest Reasonable Interpretation
Cuozzo is a name that, strangely enough, reminds me of pizza. It must be the two z’s. Unfortunately, the two are unrelated even through a broadest reasonable interpretation (bad patent…
The Momentum in Tech For a Collaborative Approach to Patent Litigation
Two of the largest tech companies in the world, Google and Microsoft, announced at the end of last month that they had reached agreement to drop 20 pending patent lawsuits…
Hedge Funds and Inter Partes Review: Robin Hood or Troll?
For many, the term hedge fund does not bring pleasant thoughts to mind. These investment vehicles, typically reserved for wealthy and sophisticated investors, gained their name from the hedging techniques…
Courts Should Swipe Left on the Online Dating Patent
Trends have shown that Americans are turning to the internet to pursue new dating prospects, with online dating rates at an all-time high. However, a recently settled lawsuit against an…
Feeding the Trolls?: Commil v. Cisco and the Court’s Balancing Act
Sometimes, the devil’s in the dicta. The Supreme Court’s 6-2 decision in Commil v. Cisco rejects good-faith belief in a patent’s invalidity as a defense to induced infringement. It also…
The Legal Puzzle of the Rubik’s Cube
I have a friend who competes in Rubik’s Cube championships. He can solve those puzzles with his hands (and feet!) in seconds, and you can watch his dizzying feats on…
What to Learn from Martin Shkreli: The Media is Not Comfortable Discussing Patent Law
Turing Pharmaceuticals recently raised the price of their drug, Daraprim, dramatically from $13.50 per pill to $750 per pill. Daraprim is mainly used to treat toxoplasmosis, a complication that only…
Looking Back to Move Forward: The USPTO’s New Policy Initiative
Earlier this year, the United States Patent and Trademark Office announced an initiative to enhance the quality of patents. This new initiative comes on the heels of previous quality initiatives…